|
| |
|
| |
 |
| |
|
| |
|
| |
Statement (Excerpt) to House Ways and
Means Committee Hearing of December 06, 2006
Regarding Patient Safety and Quality Issues
in End Stage Renal Disease Treatment
Association of Dialysis Advocates
|
|
|
| |
|
| |
|
| |
Is the Reported US ESRD Mortality
Rate A Lie?
Joe Atkins, Managing Editor,
Dialysis & Transplant City
|
|
|
| |
|
| |
| |
July
26, 2007 |
| |
EPOGEN
Ways & Means
Truth Squad:
What they
don't want
you to
know about
Anemia
Management
Care
U.
S. Congress,
House Committee
on Ways & Means
|
|
|
| |
|
| |
| |
July
20, 2007 |
| |
EPOGEN
Medicare to Modify Its Claims Monitoring Policy for
Use of Erythropoiesis Stimulating Agents (ESAs) for
Anemia Treatment in Dialysis
Centers for Medicare & Medicaid
Services (CMS); July 20, 2007
|
|
|
| |
|
| |
|
| |
EPOGEN
Conflicted Kidney Docs Snub FDA on EPO
Permission Granted: Merrill Goozner,
Director, Integrity in Science, Center for
Science in the Public Interest (042207)
|
|
|
| |
|
| |
|
| |
EPOGEN
Medicare Reviewing Erythropoiesis Stimulating
Agents (ESAs) Policies in Response to FDA's
Recent Black Box Warning and Public Health
Advisories
U. S. Department
of Health & Human Services, Centers for Medicare & Medicaid Services
|
|
|
| |
|
| |
|
| |
EPOGEN
Analysis: Payment System's
Role in Overly Aggressive Use of
Biologic Anemia Drugs
Permission Granted: Milton
R. Benjamin, Editor and Publisher,
Biologic Drug Report (031307)
|
|
|
| |
|
| |
|
| |
EPOGEN
FDA Strengthens Safety
Information for Erythropoiesis-Stimulating
Agents (ESAs)
U.S. Food and Drug Administration
|
|
|
| |
|
| |
|
| |
|
| |
|
| |
FDA Patient Safety News
Cardiovascular Risk with Erythropoietic
Agents
|
|
|
| |
|
| |
|
| |
EPOGEN
EPO Adjustments in Patients With Elevated
Hemoglobin Levels: Provider Practice Patterns
Compared With Recommended Practice Guidelines
American Journal of Kidney Diseases (AJKD)
Allan J. Collins, MD,
FACP; James P. Ebben, BS; David T. Gilbertson,
Ph.D; December 12, 2006 (122306)
|
|
|
| |
|
| |
|
| |
Permission granted: Joe
Atkins, Managing Editor, Dialysis & Transplant
City (121006)
|
|
|
| |
|
| |
|
| |
House Ways and Means Committee Hearing
on Patient Safety and Quality Issues in End
Stage Renal Disease Treatment
Statement of The Honorable David M. Walker,
Comptroller General, US Government Accountability
Office (GAO)
Testimony Before the House Committee on
Ways and Means, December 6, 2006
|
|
|
| |
|
| |
|
| |
House Ways and Means Committee Hearing
on Patient Safety and Quality Issues in End
Stage Renal Disease Treatment
Statement of Leslie V. Norwalk, Acting
Administrator, Centers for Medicare and Medicaid
Services
Testimony Before the House Committee on
Ways and Means, December 6, 2006
|
|
|
| |
|
| |
|
| |
House Ways and Means Committee Hearing
on Patient Safety and Quality Issues in End
Stage Renal Disease Treatment
Statement of Ajay K. Singh, Associate
Professor of Medicine, Bringham and Women's
Hospital, Harvard Medical School, Massachusetts
Testimony Before the House Committee on
Ways and Means, December 6, 2006
|
|
|
| |
|
| |
|
| |
House Ways and Means
Committee Hearing on Patient
Safety and Quality Issues
in End Stage Renal Disease
Treatment
Statement of Laura T.
Pizzi, Research Associate
Professor of Health Policy,
Department of Health Policy,
Thomas Jefferson University,
Philadelphia, Pennsylvania
Testimony Before the
House Committee on Ways
and Means, December 6,
2006
|
|
|
| |
|
| |
|
| |
House Ways and Means
Committee Hearing on Patient
Safety and Quality Issues
in End Stage Renal Disease
Treatment
Statement of Dennis
J. Cotter, President, Medical
Technology and Practice
Patterns Institute, Inc.,
Bethesda, Maryland
Testimony Before the
House Committee on Ways
and Means, December 6,
2006
|
|
|
| |
|
| |
|
| |
House Ways and Means Committee
Hearing on Patient Safety and
Quality Issues in End Stage Renal
Disease Treatment, December 6,
2006
Statement of American Society
of Pediatric Nephrology, Indianapolis,
Indiana
|
|
|
| |
|
| |
|
| |
House Ways and Means Committee
Hearing on Patient Safety and
Quality Issues in End Stage Renal
Disease Treatment
Statement of Richard Carrancejie,
Dialysis Patient, Birmingham,
Alabama
|
|
|
| |
|
| |
|
| |
House Ways and Means Committee
Hearing on Patient Safety and
Quality Issues in End Stage Renal
Disease Treatment, December 6,
2006
Statement of Davita Patient
Citizens
|
|
|
| |
|
| |
|
| |
House Ways and Means Committee
Hearing on Patient Safety and
Quality Issues in End Stage Renal
Disease Treatment, December 6,
2006
Statement of American Society
of Nephrology
|
|
|
| |
|
| |
|
| |
EPOGEN
House Ways and Means Committee
Hearing on Patient Safety and
Quality Issues in End Stage Renal
Disease Treatment, December 6,
2006
Statement of Noshi Ishak,
M.D., CEO, Medical Director,
Central New Hampshire Kidney
Center, Laconia, New Hampshire
|
|
|
| |
|
| |
|
| |
House Ways and Means Committee
Hearing on Patient Safety and Quality
Issues in End Stage Renal Disease
Treatment, December 6, 2006
Statement of Kidney Care Partners
|
|
|
| |
|
| |
|
| |
House Ways and Means Committee
Hearing on Patient Safety and Quality
Issues in End Stage Renal Disease
Treatment, December 6, 2006
Statement of National Kidney Foundation,
Inc., New York, New York
|
|
|
| |
|
| |
|
| |
House Ways and Means Committee Hearing
on Patient Safety and Quality Issues
in End Stage Renal Disease Treatment,
December 6, 2006
Statement of Renal Physicians Associations,
Rockville, Maryland
|
|
|
| |
|
| |
|
| |
House Ways and Means Committee Hearing
on Patient Safety and Quality Issues
in End Stage Renal Disease Treatment,
December 6, 2006
Statement of Kris Robinson, American
Association of Kidney Patients, Tampa,
Florida
|
|
|
| |
|
| |
|
| |
House Ways and Means Committee Hearing
on Patient Safety and Quality Issues in
End Stage Renal Disease Treatment, December
6, 2006
State of Dori Schatell, Medical Education
Institute, Madison, Wisconsin
|
|
|
| |
|
| |
|
| |
EPOGEN
House Ways and Means Committee Hearing
on Patient Safety and Quality Issues in End
Stage Renal Disease Treatment, December 6,
2006
Statement of Coalition for Dialysis Patient
Choice
|
|
|
| |
|
| |
|
| |
House Ways and Means Committee Hearing on
Patient Safety and Quality Issues in End Stage
Renal Disease Treatment, December 6, 2006
Statement of Patricia Tate-Harris, Association
of Dialysis Advocates, Baton Rouge, Louisiana
|
|
|
| |
|
| |
|
| |
EPOGEN
ADVISORY: Thomas
Announces Hearing on Patient Safety and Quality
Issues in End Stage Renal Disease Treatment
U.S. House of Representatives, Ways and Means
Committee
|
|
|
| |
|
| |
|
| |
US Food and Drug Administration ALERT Information
for Healthcare Professionals Erythropoiesis
Stimulating Agents (ESA)
Aranesp, Epogen
and Procrit
|
|
|
| |
|
| |
|
| |
EPOGEN
GAO Report to the Chairman, Committee on Ways and Means, House of Representatives
END-STAGE RENAL DISEASE
Bundling
Medicare's Payment for Drugs with Payment
for All ESRD Services Would Promote Efficiency
and Clinical Flexibility U. S. Government
General Accountability Office-07-77
|
|
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
